2019年底，自中國武漢地區開始流行的急性呼吸症候群大規模擴散以來，全球的醫療系統和公衛體系受到了莫大的威脅。醫療系統的樣貌正在慢慢改變，尤其是針對慢性病的照護也面臨許多挑戰。骨質疏鬆症正是在此浪潮當中明顯被影響的慢性疾病之一。根據統計，全球的骨質疏鬆症從診斷、治療到追蹤，在這段時間和過去相比有著巨大的改變。因此，對於這襲捲而來的變化，我們必須要以新的思維和決策模式來處理這個年長者中隱形的殺手。本文旨在藉由回顧實證醫學和文獻，提供臨床工作者於疫情期間處理骨質疏鬆症時，從評估診斷，實驗室數據的蒐集，骨鬆藥物的特殊考量和轉換，與配合疫情可進行的復健活動做完整介紹。我們同時也會就骨鬆藥物和新冠肺炎的風險，以及新冠肺炎的疫苗接種做通盤的探討。

Coronavirus disease of 2019(COVID-19) is a highly contagious viral disease, causing reparatory symptoms, ranging from flu-like symptoms to acute respiratory distress. Since the end of 2019, COVID-19 has posed a tremendous threat to the healthcare systems nationwide. Multiple public health interventions, including mandating social distancing, closing outpatient visits, or postponing elective procedures have been implemented to mitigate the impact on disease transmission and prevent consumption of medical resources. Since the beginning of the pandemic, resources have been shifted away from chronic disease management and prevention. Osteoporosis, a chronic condition, which requires continuous and concerted medical attention to alleviate the long-term consequences such as osteoporotic fractures, morbidities, or mortalities. In this review article, we will discuss the strategies to cope with osteoporosis, especially focusing on pharmaceutical management considerations during the era of COVID-19 pandemic. We will also discuss different drug distribution models when outpatient clinics are not readily available or mandatory social distancing policy is employed. After all, we will propose alternative therapeutic options when the continuity of particular medications cannot be maintained.